News & Updates

910, 2018

Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines

October 9th, 2018|

PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) Guidelines The NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for Read More

2308, 2018

US Oncology Research Joins Agendia’s FLEX Big Data Initiative, Accelerating Diagnostic Discoveries in Breast Cancer and Enabling Precision Oncology

August 23rd, 2018|

Dataset of up to 10,000 full genome profiles matched with complete clinical data will provide representative resource for breast cancer research IRVINE, CALIF., U.S., THE WOODLANDS, TEXAS, U.S., and AMSTERDAM, NETHERLANDS (23 August 2018) – Read More